Effect of the Antioxidant Micronutrients of Rapeseed Oil on the Prevention of Cardiovascular Diseases (Optim'Oils)
NCT ID: NCT00852735
Last Updated: 2010-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2008-12-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Randomised crossover dietary intervention study:
The main objective of the clinical study is to investigate the effect of the consumption of an "optimized" rapeseed oil on the lipid metabolism of volunteers as compared with the consumption of a "reference" oil.
Post prandial study:
The second objective of the clinical study is to investigate the effect of the consumption of an "optimized" rapeseed oil on the biomarkers of oxidative stress during post prandial period as compared with the consumption of a "reference" oil.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study on the Lipid-lowering Effect of Plant Sterols and Fish Oil
NCT01313988
Fish Oil and Cardiovascular Suboptimal Health
NCT02103517
Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
NCT00504309
Does Consuming Modified Plant Seed Oil Containing Fish Oil Fatty Acids Act in the Same Way as Consuming Fish Oil?
NCT03477045
The Effect of n-3 LCPUFA on Immune Function and Cardiovascular Risk Factors
NCT00266292
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Randomised crossover dietary intervention study:
Sixty volunteers will be randomised into 2 groups of 30. The study will last 12weeks. The first 3 weeks will be an adaptation period or "run in". Volunteers will have every day20 g of the reference rapeseed oil and 20 g of the reference oil-based rapeseed margarine. Subsequently, the two groups will follow 2 dietary intervention periods of 3 weeks during which the volunteers will have alternatively either the reference oil/margarine or the optimized oil/margarine. Three weeks of "wash out" will separate the two dietary interventions of the cross over design trial.
Cardiovascular risk and oxidative stress biomarkers will be assessed in plasma at week 0, 3, 6, 9 and 12.
Volunteers will alsoperform dietary surveys at the week 3, 6, 9 and 12.
Post prandial study:
16 volunteers will be cast lots among the 60 volunteers. They will be randomised into 2 groups of 8. The first kinetic study will be done on week 3. 8 subjects will take 66 g of reference oil and 8 subjects will take 66 g of the optimized oil. 5 blood samples (20 mL each) will be taken.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rapeseed Oil (prevention of cardiovascular diseases)
to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age : 30 to 65
* Body mass index between 25 and 30 kg/m²
* Weight lower than 110 kg
* Subject considered as normal after clinical examination and medical questionnaire
* Subject giving his written informed consent
* Subject willing to comply with the study procedures
* Affiliated to National Health Insurance
Exclusion Criteria
* Positive serologies to HIV or HCV
* Previous medical and/or surgery judged by the investigator as incompatible with the study
* Taking medicine: hypocholesterolemic,beta blockers, IEC,
* Diabetes1 and 2
* High blood pressure
* Digestive, cardiovascular, renal, liver, tumor or thyroid diseases in the last 5 years
* Infectious or inflammatory diseases in the last 5 years
* Previous heavy intestine surgery (except appendectomy)
* Triglycerides\> 4 g/L
* Dyslipidemia: HDL cholesterol\< 0.4 g/L or LDL/HDL\>6.25
* blood donation done less than 2 month before the start of the study
* Particular diet: vegetarian, vegan...
* Anormal dietary habits
* Consumption of food complements: antioxidant, ...
* intense physical exercise practise (\>5 h per week)
* Tobacco, alcohol:more than 30 g of alcohol/day, i.e.3 glasses/day, smoking \> 5 cigarettes /day
* No affiliated to National Health Insurance people
* Refusal to sign informed consent
* Refusal to be registered on the National Volunteers Data file
* Currently participating or who having got 4500 E in this year before to have participated in another clinical trial
30 Years
65 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre de Recherche en Nutrition Humaine d'Auvergne
OTHER_GOV
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
OTHER
ITERG
INDUSTRY
Unilever R&D
INDUSTRY
Lesieur
INDUSTRY
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CRNH Auvergne
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Noël Cano
Role: PRINCIPAL_INVESTIGATOR
Centre de Recherche en Nutrition Humaine d'Auvergne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CRNH Auvergne
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AU 759
Identifier Type: -
Identifier Source: secondary_id
CHU-0047
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.